Clinical Study Deep Sclerectomy with Nonabsorbable Implant (T-Flux) in Patients with Pseudoexfoliation Glaucoma Pavel Studeny, 1 Alina-Dana Baxant, 1 Jana Vranova, 2 Pavel Kuchynka, 1 and Jitka Pokorna 1 1 Department of Ophthalmology, University Hospital Kralovske Vinohrady, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic 2 Department of Medical Biophysics and Informatics, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic Correspondence should be addressed to Alina-Dana Baxant; alinadana.baxant@seznam.cz Received 23 October 2016; Accepted 26 December 2016; Published 15 January 2017 Academic Editor: Colin Clement Copyright © 2017 Pavel Studeny et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Purpose. To evaluate the efectiveness of deep sclerectomy with T-fux implant (DS T-fux) in patients with pseudoexfoliation glaucoma (PExG). Methods. 20 eyes of 18 patients with medically uncontrolled PExG have undergone DS T-fux implantation. Postoperatively we evaluated the IOP values and the frequency of complications. Te minimum follow-up time was 12 months (20 eyes) and the maximum 24 months (10 eyes). Results. Te mean preoperative IOP was 36.8 ± 8.7 mmHg. Te IOP signifcantly decreased throughout all postoperative periods ( < 0.05) and reached 1 day afer surgery 11.45 ± 6.6 mmHg; 3 months 13.45 ± 3.6 mmHg; 12 months 14 ± 2.8 mmHg; and 24 months 14.80 ± 2.4 mmHg. Complete success rate, defned as IOP ≤ 18mmHg without medication, was 85% (17/20 eyes) at 12 months. Qualifed success rate, defned as IOP ≤ 18 mmHg with or without medication, was 100% (20/20 eyes). Te most frequent postoperative complications were mild hyphaema (9 patients, 45%), choroidal detachment (3 patients, 15%), and hypotony—IOP < 5 mmHg (2 patients, 10%). Conclusions. DS with T-fux implant is a safe and efective surgical treatment method for medically uncontrolled PExG. Te number of complications is low. 1. Introduction Pseudoexfoliation syndrome (PEx) is an age-related systemic disease characterized by the production and accumulation of an abnormal fbrillar material as small, whitish deposits in many ocular and extraocular tissues [1–3]. It was frst described by Lindberg in 1917 [4, 5]. Te reported prevalence of PEx varies from 0.2% to 30% in diferent studies and populations; in European countries it is reported as being between 4 and 6.5% [6–16]. In many of these patients a special type of secondary glaucoma progressively develops— pseudoexfoliation glaucoma (PExG). Te percentage of patients with PEx who develop secondary glaucoma varies in diferent studies. In one series of 100 consecutive subjects with PEx, glaucoma was detected in 7% and ocular hypertension in 15% of patients [17]. In the Jeng et al. study, 16% of patients with PEx initially had antiglaucoma therapy, and, in the remaining patients, the probability of being placed on therapy was 44% at 15 years [18]. In the Grodum study, afer a mean of 8.7 years, 54 out of 98 patients (55.1%) with PEx had developed glaucoma [19]. PExG is thought to arise secondarily to congestion of the trabecular meshwork by pseudoexfoliative material. It is the most common form of secondary open-angle glaucoma. In general, PExG in comparison with primary open-angle glaucoma (POAG) has a greater resistance to medicamentous treatment, rapid progression, higher diurnal intraocular pres- sure (IOP), fuctuation, and poor prognosis [19–22]. If medical treatment is not sufcient to manage PExG, subsequent interventions are surgical, typically comprising laser trabeculoplasty, trabeculectomy, and the implantation of a glaucoma drainage device [20]. Deep sclerectomy (DS) is a nonpenetrating fltration pro- cedure for the surgical treatment of medically uncontrolled open-angle glaucoma. It was designed in an attempt to lower the risk of the incidence of some postoperative complications afer penetrating glaucoma surgery and thus ofers both surgeons and patients a safer, more convenient option [23– 25]. An evaluation of the efectiveness of deep sclerectomy and nonabsorbable glaucoma implants in patients with PExG is the main aim of this work. Hindawi Journal of Ophthalmology Volume 2017, Article ID 6923208, 5 pages https://doi.org/10.1155/2017/6923208